Verve’s Base Editor “Numerically Beats” Other Cholesterol-Lowering Drugs
In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli Lilly and a showdown with Novartis.
Verve’s Base Editor “Numerically Beats” Other Cholesterol-Lowering Drugs Read More »
